Conditions: Migraine Disorders
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 514
Healthy volunteers: no

Brief summary:
This study will use an open-label design to evaluate the safety of NP101. Adult subjects who meet the enrollment criteria will be treated with NP101 (sumatriptan succinate iontophoretic transdermal patch) for acute migraine attacks over a 12 month period.

Detailed description:

Arms:
arm 1: sumatriptan iontophoretic transdermal patch

Interventions: intervention 1: NP101
Intervention descriptions: intervention 1: NP101 study patch four hour application

Protocol document: